Jushi Holdings (JUSHF) Non-Current Assets (2021 - 2026)
Jushi Holdings' (JUSHF) quarterly Non-Current Assets came in at $350.5 million in Q1 2026, down 3.98% year-on-year from $365.0 million in Q1 2025, and down 1.01% on a QoQ basis from $354.0 million in Q4 2025.
Jushi Holdings (JUSHF) Non-Current Assets (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Non-Current Assets data on file, last reported at $350.5 million in Q1 2026.
- On a quarterly basis, Non-Current Assets fell 3.98% year-over-year to $350.5 million in Q1 2026; TTM through Mar 2026 was $350.5 million, a 3.98% decrease from a year earlier, with the FY2025 full-year figure at $354.0 million, down 3.84% from the prior year.
- Non-Current Assets for Q1 2026 stood at $350.5 million, down from $354.0 million in the prior quarter.
- Over the last five years, Non-Current Assets for JUSHF reached as high as $613.5 million in Q2 2022 and fell as low as $350.5 million in Q1 2026.
- Historically, Non-Current Assets has averaged $418.4 million across 5 years, with a median of $374.8 million in 2024.
- Across the five-year window, Non-Current Assets plunged 32.97% in 2023 and increased 0.64% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $459.3 million in 2022, then slipped by 16.88% to $381.8 million in 2023, then fell by 3.56% to $368.2 million in 2024, then slipped by 3.84% to $354.0 million in 2025, then declined by 1.01% to $350.5 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $350.5 million in Q1 2026, $354.0 million in Q4 2025, and $363.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | 350.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 350.46 Mn |
| Dec 31, 2025 | 354.03 Mn |
| Sep 30, 2025 | 363.10 Mn |
| Jun 30, 2025 | 368.14 Mn |
| Mar 31, 2025 | 364.97 Mn |
| Dec 31, 2024 | 368.17 Mn |
| Sep 30, 2024 | 360.79 Mn |
| Jun 30, 2024 | 366.45 Mn |
| Mar 31, 2024 | 374.85 Mn |
| Dec 31, 2023 | 381.76 Mn |
| Sep 30, 2023 | 400.41 Mn |
| Jun 30, 2023 | 411.20 Mn |
| Mar 31, 2023 | 454.94 Mn |
| Dec 31, 2022 | 459.29 Mn |
| Sep 30, 2022 | 584.54 Mn |
| Jun 30, 2022 | 613.49 Mn |
| Mar 31, 2022 | 536.92 Mn |
| Dec 31, 2021 | 497.69 Mn |